Global Somatic Genetic Testing Market

Somatic Genetic
Testing Market
Focus on Product Type, Sample,
Technology, Applications, End Users,
Country Data (15 Countries), and
Competitive Landscape: Analysis and
Forecast: 2020-2030
March 2021
TOC
Analysis and Forecast: 2018-2023

Global Somatic Genetic Testing Market
All rights reserved at BIS Research 2
BIS Research is a leading market intelligence and technology research company. BIS Research
publishes in-depth market intelligence reports focusing on the market estimations, technology
analysis, emerging high-growth applications, deeply segmented granular country-level market data
and other important market parameters useful in the strategic decision making for senior
management. BIS Research provides multi-client reports, company profiles, databases, and custom
research services.
Copyright © 2021 BIS Research
All Rights Reserved. This document contains highly confidential information and is the sole property
of BIS Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents
of this document is strictly prohibited. Access to this information is provided exclusively for the benefit
of the people or organization concerned. It may not be accessed by or offered whether for sale or
otherwise to any third party.

Table of Contents
Executive Summary……………………………………………...……………. 24
1. Product Definition .......................................................................................32
1.1 Inclusion and Exclusion ....................................................................32
2. Market Scope ...............................................................................................33
2.1 Scope of the Study.............................................................................33
2.2 Key Questions Answered in the Report...........................................34
3. Research Methodology ...............................................................................35
3.1 Global Somatic Genetic Testing Market: Research Methodology .35
3.2 Data Sources ......................................................................................36
3.2.1 Primary Data Sources .........................................................36
3.2.2 Secondary Data Sources ....................................................37
3.3 Market Estimation Model...................................................................37
3.4 Criteria for Company Profiling..........................................................40
4. Market Overview..........................................................................................41
4.1 Market Definition................................................................................41
4.2 Market Footprint and Growth Potential, $Million, 2019-2030..........41
4.3 Commercialized Assays and Applications ......................................42
4.4 COVID-19 Impact: Global Somatic Genetic Testing Market............43
5. Industry Insights..........................................................................................45
5.1 Overview .............................................................................................45
5.2 Legal Requirements and Framework in U.S. ...................................45
5.2.1 FDA Regulation ...................................................................45
5.2.2 CMS Regulation...................................................................47
5.3 Legal Requirements and Framework in Europe ..............................47
5.4 Legal Requirements and Framework in Asia-Pacific ......................48
5.4.1 China ....................................................................................48
5.4.2 Japan....................................................................................49

5.5 Reimbursement Analysis ..................................................................50
6. Market Dynamics.........................................................................................52
6.1 Overview .............................................................................................52
6.2 Iceberg Analysis.................................................................................52
6.3 Impact Analysis..................................................................................54
6.4 Market Drivers ....................................................................................55
6.4.1 Global Increase in Cancer Prevalence...............................55
6.4.2 Increasing Consumer Awareness for Tailored Cancer
Therapy ................................................................................57
6.4.3 Decreasing Cost of Sequencing ........................................58
6.4.4 Increasing Adoption of Inorganic Growth Strategies in the
Market...................................................................................59
6.5 Market Restraints ...............................................................................60
6.5.1 Uncertain Reimbursement and Regulatory Policies ........60
6.5.2 Lack of Trained Professionals in the Field of Oncology..61
6.5.3 Lack of Established Treatment Protocols for High-Valued
Cancer Tests in Emerging Economies ..............................62
6.6 Market Opportunities .........................................................................62
6.6.1 Technological Advancements in the Field of Cancer
Genomics.............................................................................62
6.6.2 Massive Scope for Adoption of NGS-based Somatic
Genetic Tests in Emerging Markets...................................63
7. Competitive Landscape ..............................................................................65
7.1 Product Launches and Upgradations...............................................65
7.2 Product Approvals .............................................................................67
7.3 Synergistic Activities.........................................................................68
7.4 Acquisitions........................................................................................69
7.5 Market Share Analysis, by Company, 2018–2019............................69
7.6 Growth Share Analysis......................................................................71
7.6.1 Growth Share Analysis (by Company) ..............................71
7.6.2 Growth Share Analysis (by Technology)...........................73

8. Global Somatic Genetic Testing Market (by Product Type),
$Million, 2019-2030......................................................................................76
8.1 Overview .............................................................................................76
8.2 Products..............................................................................................77
8.2.1 Kits and Assays...................................................................79
8.2.2 Instruments..........................................................................81
8.2.3 Software ...............................................................................83
8.3 Services ..............................................................................................85
9. Global Somatic Genetic Testing Market (by Sample),
$Million, 2019-2030......................................................................................88
9.1 Overview .............................................................................................88
9.2 Tissue-Based......................................................................................89
9.3 Blood-Based.......................................................................................91
9.4 Bone Marrow Aspirates .....................................................................92
9.5 Other Samples....................................................................................93
10. Global Somatic Genetic Testing Market (by Technology),
$Million, 2019-2030......................................................................................95
10.1 Overview .............................................................................................95
10.2 Sequencing.........................................................................................96
10.2.1 Next-Generation Sequencing (NGS) ..................................98
10.2.1.1 Sequencing by Synthesis.................................................99
10.2.1.2 Other Next-Generation Sequencing Technologies.........101
10.2.2 Traditional Sequencing.....................................................102
10.3 Polymerase Chain Reaction (PCR) .................................................103
10.3.1 Real-Time Polymerase Chain Reaction (RT-PCR) ..........105
10.3.2 Digital Polymerase Chain Reaction (dPCR) ....................107
10.4 Microarray.........................................................................................108
10.5 Other Technologies .........................................................................110
11. Global Somatic Genetic Testing Market (by Application),
$Million, 2019-2030....................................................................................112

11.1 Overview ...........................................................................................112
11.2 Solid Tumors ....................................................................................113
11.2.1 Breast Cancer....................................................................115
11.2.2 Prostate Cancer.................................................................118
11.2.3 Colorectal Cancer (CRC)...................................................120
11.2.4 Lung Cancer ......................................................................123
11.2.5 Liver Cancer.......................................................................125
11.2.6 Ovarian Cancer..................................................................128
11.2.7 Other Solid Tumors...........................................................130
11.3 Hematological Malignancies ...........................................................131
11.3.1 Leukemia............................................................................133
11.3.2 Lymphoma .........................................................................135
11.3.3 Myeloma.............................................................................137
12. Global Somatic Genetic Testing Market (by End User),
$Million, 2019-2030....................................................................................140
12.1 Overview ...........................................................................................140
12.2 Academic and Research Institutions .............................................141
12.3 Hospitals and Diagnostic Laboratories..........................................143
12.4 Pharmaceutical and Biotechnology Companies ...........................145
12.5 Contract Research Organizations (CROs) .....................................146
12.6 Other End Users...............................................................................147
13. Global Somatic Genetic Testing Market (by Region),
$Million, 2019-2030....................................................................................149
13.1 Overview ...........................................................................................149
13.2 North America ..................................................................................152
13.2.1 U.S. .....................................................................................154
13.2.2 Canada ...............................................................................156
13.2.3 North America Somatic Genetic Testing Market
(by Application), 2019-2030 ..............................................158
13.3 Europe...............................................................................................159
13.3.1 Germany.............................................................................163

13.3.2 U.K. .....................................................................................164
13.3.3 France.................................................................................165
13.3.4 Italy .....................................................................................167
13.3.5 Spain...................................................................................169
13.3.6 Netherlands........................................................................170
13.3.7 Rest-of-Europe ..................................................................171
13.3.8 Europe Somatic Genetic Testing Market (by Application),
2019-2030 ...........................................................................172
13.4 Asia-Pacific.......................................................................................173
13.4.1 China ..................................................................................176
13.4.2 Japan..................................................................................178
13.4.3 India....................................................................................180
13.4.4 Australia.............................................................................181
13.4.5 South Korea.......................................................................182
13.4.6 Rest-of-Asia-Pacific...........................................................184
13.4.7 Asia-Pacific Somatic Genetic Testing Market (by
Application), 2019-2030....................................................185
13.5 Latin America ...................................................................................186
13.5.1 Brazil...................................................................................189
13.5.2 Mexico ................................................................................190
13.5.3 Rest-of-Latin America .......................................................191
13.5.4 Latin America Somatic Genetic Testing Market (by
Application), 2019–2030....................................................192
13.6 Rest-of-the-World (RoW) .................................................................193
14. Company Profiles......................................................................................195
14.1 Overview ...........................................................................................195
14.2 Agilent Technologies, Inc................................................................196
14.2.1 Company Overview ...........................................................196
14.2.2 Role of Agilent Technologies, Inc. in the Global Somatic
Genetic Testing Market.....................................................196
14.2.3 Financials...........................................................................197
14.2.4 Key Insights About Financial Health of the Company ...200

14.2.5 SWOT Analysis..................................................................201
14.3 ARUP Laboratories ..........................................................................202
14.3.2 Role of ARUP Laboratories in the Global Somatic Genetic
Testing Market...................................................................202
14.3.3 SWOT Analysis..................................................................204
14.4 ASURAGEN Inc. ...............................................................................205
14.4.2 Role of ASURAGEN Inc. in the Global Somatic Genetic
Testing Market...................................................................205
14.4.3 SWOT Analysis..................................................................207
14.5 Beijing Genomics Institute (BGI) Genomics Co., Ltd....................208
14.5.2 Role of Beijing Genomics Institute (BGI) Genomics Co.,
Ltd in the Global Somatic Genetic Testing Market.........208
14.5.3 SWOT Analysis..................................................................210
14.6 bioMérieux S.A. ................................................................................211
14.6.2 Role of bioMérieux S.A. in the Global Somatic Genetic
Testing Market...................................................................211
14.6.3 Financials...........................................................................212
14.6.5 SWOT Analysis..................................................................215
14.7 CENTOGENE N.V. ............................................................................216
14.7.2 Role of CENTOGENE N.V. in the Global Somatic Genetic
Testing Market...................................................................216
14.7.3 Financials...........................................................................217
14.7.5 SWOT Analysis..................................................................221
14.8 CIRCULOGENE Theranostics, LLC ................................................222

14.8.2 Role of CIRCULOGENE Theranostics, LLC in the Global
Somatic Genetic Testing Market......................................222
14.8.3 SWOT Analysis..................................................................224
14.9 F. Hoffmann-La Roche Ltd. .............................................................225
14.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Somatic
14.9.3 Financials...........................................................................227
14.9.5 SWOT Analysis..................................................................231
14.10Guardant Health, Inc. .......................................................................232
14.10.2 Role of Guardant Health, Inc. in the Global Somatic
14.10.3 Financials...........................................................................234
14.10.4 SWOT Analysis..................................................................237
14.11Illumina, Inc. .....................................................................................238
14.11.2 Role of Illumina, Inc. in the Global Somatic Genetic
Testing Market...................................................................238
14.11.3 Financials...........................................................................240
14.11.5 SWOT Analysis..................................................................244
14.12Invivoscribe, Inc...............................................................................245
14.12.2 Role of Invivoscribe, Inc. in the Global Somatic Genetic
Testing Market...................................................................245
14.12.3 SWOT Analysis..................................................................247
14.13Laboratory Corporation of America Holdings ...............................248
14.13.2 Role of Laboratory Corporation of America Holdings in
the Global Somatic Genetic Testing Market....................248
14.13.3 Financials...........................................................................250

14.13.4 SWOT Analysis..................................................................253
14.14Mission Bio.......................................................................................254
14.14.2 Role of Mission Bio in the Global Somatic Genetic Testing
Market.................................................................................254
14.14.3 SWOT Analysis..................................................................255
14.15NeoGenomics Laboratories, Inc. ....................................................256
14.15.2 Role of NeoGenomics Laboratories, Inc. in the Global
14.15.3 Financials...........................................................................258
14.15.4 Key Insights about Financial Health of the Company....259
14.15.5 SWOT Analysis..................................................................260
14.16OmniSeq ...........................................................................................261
14.16.2 Role of Omniseq in the Global Somatic Genetic Testing
Market.................................................................................261
14.16.3 SWOT Analysis..................................................................262
14.17Oxford Nanopore Technologies Ltd. ..............................................263
14.17.2 Role of Oxford Nanopore Technologies Ltd. in the Global
14.17.3 SWOT Analysis..................................................................264
14.18Pacific Biosciences of California, Inc.............................................265
14.18.2 Role of Pacific Biosciences of California, Inc. in the Global
14.18.3 Financials...........................................................................266
14.18.5 SWOT Analysis..................................................................270
14.19QIAGEN N.V......................................................................................271

14.19.2 Role of QIAGEN N.V. in the Global Somatic Genetic
Testing Market...................................................................271
14.19.3 Financials...........................................................................273
14.19.5 SWOT Analysis..................................................................277
14.20Quest Diagnostics Incorporated.....................................................278
14.20.2 Role of Quest Diagnostics Incorporated in the Global
14.20.3 Financials...........................................................................280
14.20.4 SWOT Analysis..................................................................282
14.21Thermo Fisher Scientific Inc. ..........................................................283
14.21.2 Role of Thermo Fisher Scientific Inc. in the Global
14.21.3 Financials...........................................................................285
14.21.5 SWOT Analysis..................................................................288

List of Tables
Table 4.1: Key Somatic Genetic Testing Assays .............................................................................43
Table 5.1: Key Coverage Providers for Somatic Genetic Testing ....................................................51
Table 6.1: Likert Scale .....................................................................................................................54
Table 6.2: Impact Analysis of Market Drivers...................................................................................54
Table 6.3: Impact Analysis of Market Restraints..............................................................................55
Table 8.1: Kits and Assays Offered by Key Players.........................................................................81
Table 8.2: Instruments Offered by Key Players................................................................................83
Table 8.3: Software Offered by Key Players....................................................................................85
Table 8.4: Services Offered by Key Players ....................................................................................87
Table 11.1: Somatic Genetic Testing Products for Breast Cancer.................................................117
Table 11.3: Somatic Genetic Testing Products for Prostate Cancer..............................................120
Table 11.5: Somatic Genetic Testing Products for Colorectal Cancer ...........................................122
Table 11.6: Somatic Genetic Testing Products for Colorectal Cancer ...........................................122
Table 11.7: Somatic Genetic Testing Products for Lung Cancer ...................................................125
Table 11.8: Somatic Genetic Testing Products for Lung Cancer ...................................................125
Table 11.9: Somatic Genetic Testing Products for Liver Cancer....................................................127
Table 11.10: Somatic Genetic Testing Products for Liver Cancer..................................................127
Table 11.11: Somatic Genetic Testing Products for Ovarian Cancer.............................................130
Table 11.12: Somatic Genetic Testing Products for Ovarian Cancer.............................................130
Table 11.13: Somatic Genetic Testing Products for Leukemia ......................................................135
Table 11.14: Somatic Genetic Testing Products for Leukemia ......................................................135
Table 11.15: Somatic Genetic Testing Products for Lymphoma....................................................137
Table 11.16: Somatic Genetic Testing Products for Lymphoma....................................................137

List of Figures
Figure 1: National Cancer Institute (NCI) of the U.S., Fiscal Budget Year-on-Year, 2013-2018......25
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Somatic Genetic
Testing Market................................................................................................................26
Figure 3: Global Somatic Genetic Testing Market (by Product Type), $Million, 2019 Vs. 2030 ......27
Figure 4: Global Somatic Genetic Testing Market (by Sample), $Million, 2019 Vs. 2030.................28
Figure 5: Global Somatic Genetic Testing Market (by Technology), $Million, 2019 vs. 2030..........29
Figure 6: Global Somatic Genetic Testing Market (by Application), $Million, 2019 vs. 2030............29
Figure 7: Global Somatic Genetic Testing Market (by End User), $Million, 2019 vs. 2030 ..............30
Figure 8: Global Somatic Genetic Testing: Market Snapshot...........................................................31
Figure 2.1: Global Somatic Genetic Testing, Market Segmentation.................................................33
Figure 3.1: Global Somatic Genetic Testing Market: Methodology ..................................................35
Figure 3.2: Primary Research Methodology.....................................................................................36
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis) ............................................................38
Figure 3.4: Top-Down Approach (Segment-Wise Analysis).............................................................38
Figure 4.1: Global Somatic Genetic Testing Market, $Million, 2019-2030........................................42
Figure 4.2: Global Somatic Genetic Testing Market: COVID-19 Impact...........................................44
Figure 6.1: Iceberg Analysis – Global Somatic Genetic Testing Market...........................................53
Figure 6.2: Global Cancer Burden, 2018 .........................................................................................56
Figure 6.3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025) ....58
Figure 6.4: Synergistic Activities, FY2019-FY2020..........................................................................60
Figure 7.1: Share of Key Developments and Strategies, January 2018–December 2020 ...............65
Figure 7.2: Share of Product Launched and Upgradations (by Company),
January 2018–December 2020 ......................................................................................66
Figure 7.3: Share of Product Approvals (by Company), January 2018-December 2020 .................67
Figure 7.4: Share of Synergistic Activities (by Company), January 2018- December 2020 .............68
Figure 7.5: Share of Acquisitions (by Company), January 2018-December 2020............................69
Figure 7.6: Market Share Analysis for Global Somatic Genetic Testing Market, 2018 and 2019 ....70

Figure 7.7: Growth Share Analysis for Global Somatic Genetic Testing Market
(by Company), 2019 .......................................................................................................72
Figure 7.8: Growth Share Analysis for Global Somatic Genetic Testing Market
(by Technology), 2019-2030...........................................................................................74
Figure 8.1: Global Somatic Genetic Testing Market (by Product Type) ...........................................76
Figure 8.2: Global Somatic Genetic Testing Market (by Product Type), 2019-2030 ........................76
Figure 8.3: Global Somatic Genetic Testing Market (by Product), $Million, 2019-2030 ...................78
Figure 8.4: Global Somatic Genetic Testing Market (by Products), 2019 and 2030.........................78
Figure 8.5: Global Somatic Genetic Testing Market (Kits and Assays), $Million, 2019-2030...........80
Figure 8.6: Global Somatic Genetic Testing Market (Instruments), $Million, 2019-2030..................82
Figure 8.7: Global Somatic Genetic Testing Market (Software), $Million, 2019-2030 ......................84
Figure 8.8: Global Somatic Genetic Testing Market (Services), $Million, 2019-2030.......................86
Figure 9.1: Global Somatic Genetic Testing Market (by Sample), $Million, 2019-2030 ...................88
Figure 9.2: Global Somatic Genetic Testing Market (by Sample), 2019 and 2030...........................89
Figure 9.3: Global Somatic Genetic Testing Market (Tissue-Based), $Million, 2019-2030..............90
Figure 9.4: Global Somatic Genetic Testing Market (Blood-Based), $Million, 2019-2030................91
Figure 9.5: Global Somatic Genetic Testing Market (Bone Marrow Aspirates),
$Million, 2019-2030 ........................................................................................................92
Figure 9.6: Global Somatic Genetic Testing Market (Other Samples), $Million, 2019-2030............93
Figure 10.1: Global Somatic Genetic Testing Market (by Technology)............................................95
Figure 10.2: Global Somatic Genetic Testing Market (by Technology), 2019 and 2030 ..................96
Figure 10.3: Global Somatic Genetic Testing Market (by Sequencing), $Million, 2019-2030...........97
Figure 10.4: Global Somatic Genetic Testing Market (by Sequencing), 2019 and 2030..................97
Figure 10.5: Global Somatic Genetic Testing Market (by NGS), $Million, 2019-2030......................98
Figure 10.6: Global Somatic Genetic Testing Market (by NGS), 2019 and 2030.............................99
Figure 10.7: Global Somatic Genetic Testing Market (SBS), $Million, 2019-2030 .........................100
Figure 10.8: Global Somatic Genetic Testing Market (Other Next-Generation Sequencing
Technologies), $Million, 2019-2030 ..............................................................................101

Figure 10.9: Global Somatic Genetic Testing Market (Traditional Sequencing),
$Million, 2019-2030 ......................................................................................................103
Figure 10.10: Global Somatic Genetic Testing Market (by PCR), $Million, 2019-2030..................104
Figure 10.11: Global Somatic Genetic Testing Market (by PCR), 2019 and 2030 .........................105
Figure 10.12: Global Somatic Genetic Testing Market (RT-PCR), $Million, 2019-2030.................106
Figure 10.13: Global Somatic Genetic Testing Market (dPCR), $Million, 2019-2030.....................107
Figure 10.14: Global Somatic Genetic Testing Market (Microarray), $Million, 2019-2030..............109
Figure 10.15: Global Somatic Genetic Testing Market (Other Technologies),
$Million, 2019-2030 .....................................................................................................110
Figure 11.1: Global Somatic Genetic Testing Market (by Application) ...........................................112
Figure 11.2: Global Somatic Genetic Testing Market (by Application), $Million, 2019-2030 .........113
Figure 11.3: Global Somatic Genetic Testing Market (by Solid Tumors), $Million, 2019-2030.......114
Figure 11.3: Global Somatic Genetic Testing Market (by Solid Tumors), 2019 and 2030..............115
Figure 11.4: Global Prevalence of Breast Cancer, (2014–2019)....................................................116
Figure 11.5: Global Somatic Genetic Testing Market (Breast Cancer), $Million, 2019-2030..........116
Figure 11.6: Global Prevalence of Prostate Cancer, (2014-2019) .................................................118
Figure 11.7: Global Somatic Genetic Testing Market (Prostate Cancer), $Million, 2019-2030......119
Figure 11.8: Global Prevalence of Colorectal Cancer (2014-2019)................................................121
Figure 11.9: Global Somatic Genetic Testing Market (Colorectal Cancer), $Million, 2019-2030....121
Figure 11.10: Global Prevalence of Lung Cancer (2014-2019)......................................................123
Figure 11.11: Global Somatic Genetic Testing Market (Lung Cancer), $Million, 2019-2030.........124
Figure 11.12: Global Prevalence of Liver Cancer (2014-2019)......................................................126
Figure 11.13: Global Somatic Genetic Testing Market (Liver Cancer), $Million, 2019-2030 .........126
Figure 11.14: Global Prevalence of Ovarian Cancer (2014-2019) .................................................128
Figure 11.15: Global Somatic Genetic Testing Market (Ovarian Cancer), $Million, 2019-2030 ....129
Figure 11.16: Global Somatic Genetic Testing Market (Other Solid Tumors),
$Million, 2019-2030 .....................................................................................................131
Figure 11.17: Global Somatic Genetic Testing Market (by Hematological Malignancies),
$Million, 2019-2030 ......................................................................................................132

Figure 11.18: Global Somatic Genetic Testing Market (by Hematological Malignancies),
2019 and 2030..............................................................................................................132
Figure 11.19: Global Prevalence of Leukemia, (2014-2019)..........................................................133
Figure 11.20: Global Somatic Genetic Testing Market (Leukemia), $Million, 2019-2030...............134
Figure 11.21: Global Prevalence of Lymphoma (2014-2019) ........................................................136
Figure 11.22: Global Somatic Genetic Testing Market (Lymphoma), $Million, 2019-2030............136
Figure 11.23: Global Prevalence of Myeloma (2014-2019)............................................................138
Figure 11.24: Global Somatic Genetic Testing Market (Myeloma), $Million, 2019-2030................138
Figure 12.1: Global Somatic Genetic Testing Market (by End User)..............................................140
Figure 12.2: Global Somatic Genetic Testing Market (by End User), $Million, 2019-2030.............141
Figure 12.3: Global Somatic Genetic Testing Market (Academic and Research Institutions),
$Million, 2019-2030 ......................................................................................................142
Figure 12.4: Global Somatic Genetic Testing Market (Hospitals and Diagnostic Laboratories),
$Million, 2019-2030 ......................................................................................................144
Figure 12.5: Global Somatic Genetic Testing Market (Pharmaceutical and Biotechnology
Companies), $Million, 2019-2030 .................................................................................145
Figure 12.6: Global Somatic Genetic Testing Market (Contract Research Organizations),
$Million, 2019-2030 ......................................................................................................147
Figure 12.7: Global Somatic Genetic Testing Market (Other End Users), $Million, 2019-2030......148
Figure 13.1: Global Somatic Genetic Testing Market (by Region) .................................................149
Figure 13.2: Global Somatic Genetic Testing Market (by Region), $Million, 2019-2030 ................150
Figure 13.3: Global Somatic Genetic Testing Market (by Region), 2019-2030 ..............................151
Figure 13.4: North America Somatic Genetic Testing Market, $Million, 2019-2030 .......................152
Figure13.5: North America: Market Dynamics ...............................................................................153
Figure 13.6: North America Somatic Genetic Testing Market (by Country),
$Million, 2019-2030 .....................................................................................................154
Figure 13.7: U.S. Somatic Genetic Testing Market, $Million, 2019-2030.......................................155
Figure 13.8: Canada Somatic Genetic Testing Market, $Million, 2019-2030 .................................157

Figure 13.9: Growth-Share Analysis for North America Somatic Genetic Testing Market
(by Application), 2019-2030..........................................................................................158
Figure 13.10: Europe Somatic Genetic Testing Market, $Million, 2019-2030 ................................160
Figure 13.11: Europe: Market Dynamics........................................................................................161
Figure 13.12: Europe Somatic Genetic Testing Market (by Country), $Million, 2019-2030............162
Figure 13.13: Germany Somatic Genetic Testing Market, $Million, 2019-2030 .............................163
Figure 13.14: U.K. Somatic Genetic Testing Market, $Million, 2019-2030.....................................165
Figure 13.15: France Somatic Genetic Testing Market, $Million, 2019-2030.................................166
Figure 13.16: Italy Somatic Genetic Testing Market, $Million, 2019-2030 .....................................168
Figure 13.17: Spain Somatic Genetic Testing Market, $Million, 2019-2030...................................169
Figure 13.18: Netherlands Somatic Genetic Testing Market, $Million, 2019-2030.........................170
Figure 13.19: Rest-of-Europe Somatic Genetic Testing Market, $Million, 2019-2030....................171
Figure 13.20: Growth-Share Analysis for Europe Somatic Genetic Testing Market
(by Application), 2019-2030..........................................................................................172
Figure 13.21: Asia-Pacific Somatic Genetic Testing Market, $Million, 2019-2030 .........................174
Figure 13.22: APAC: Market Dynamics .........................................................................................175
Figure 13.23: APAC Somatic Genetic Testing Market (by Country), $Million, 2019-2030..............176
Figure 13.24: China Somatic Genetic Testing Market, $Million, 2019-2030...................................177
Figure 13.25: Japan Somatic Genetic Testing Market, $Million, 2019-2030 ..................................179
Figure 13.26: India Somatic Genetic Testing Market, $Million, 2019-2030 ....................................180
Figure 13.27: Australia Somatic Genetic Testing Market, $Million, 2019-2030 ..............................182
Figure 13.28: South Korea Somatic Genetic Testing Market, $Million, 2019-2030 ........................183
Figure 13.29: RoAPAC Somatic Genetic Testing Market, $Million, 2019-2030..............................184
Figure 13.30: Growth-Share Analysis for Asia-Pacific Somatic Genetic Testing Market
(by Application), 2019-2030..........................................................................................185
Figure 13.31: Latin America Somatic Genetic Testing Market, $Million, 2019-2030 ......................186
Figure 13.32: Latin America: Market Dynamics .............................................................................187
Figure 13.33: Latin America Somatic Genetic Testing Market (by Country),
$Million, 2019-2030 .....................................................................................................188

Figure 13.34: Brazil Somatic Genetic Testing Market, $Million, 2019-2030...................................189
Figure 13.35: Mexico Somatic Genetic Testing Market, $Million, 2019-2030.................................190
Figure 13.36: Rest-of-Latin America Somatic Genetic Testing Market, $Million, 2019-2030.........191
Figure 13.37: Growth-Share Analysis for Latin America Somatic Genetic Testing Market
(by Application), 2019-2030..........................................................................................192
Figure 13.38: RoW Somatic Genetic Testing Market, $Million, 2019-2030....................................193
Figure 14.1: Total Number of Companies Profiled.........................................................................195
Figure 14.2: Agilent Technologies, Inc.: Product Portfolio..............................................................197
Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2017-2019.........................................197
Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019 ................................198
Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019 ...................................199
Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019 .........................................200
Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis...............................................................201
Figure 14.8: ARUP Laboratories: Product Portfolio........................................................................203
Figure 14.9: ARUP Laboratories: SWOT Analysis.........................................................................204
Figure: ASURAGEN, Inc.: Product Portfolio ..................................................................................206
Figure 14.10: ASURAGEN, Inc.: SWOT Analysis..........................................................................207
Figure 14.11: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Product Portfolio ...................209
Figure 14.12: Beijing Genomics Institute (BGI) Genomics Co., Ltd.: SWOT Analysis....................210
Figure 14.13: bioMérieux S.A.: Product Portfolio ...........................................................................212
Figure 14.14: bioMérieux S.A.: Overall Financials, 2017-2019 ......................................................212
Figure 14.15: bioMérieux S.A.: Revenue (by Segment), 2017-2019..............................................213
Figure 14.16: bioMérieux S.A.: Revenue (by Region), 2017-2019.................................................214
Figure 14.17: bioMérieux S.A.: R&D Expenditure, 2017-2019.......................................................214
Figure 14.18: bioMérieux S.A.: SWOT Analysis.............................................................................215
Figure 14.19: CENTOGENE N.V.: Portfolio...................................................................................217
Figure 14.20: CENTOGENE N.V.: Overall Financials, 2018-2020.................................................217
Figure 14.21: CENTOGENE N.V.: Sales (by Segment), 2017-2019..............................................218
Figure 14.22: CENTOGENE N.V.: Revenue (by Region), 2017-2019 ...........................................219

Figure 14.23: CENTOGENE N.V.: R&D Expenditure, 2017-2019 .................................................220
Figure 14.24: CENTOGENE N.V.: SWOT Analysis.......................................................................221
Figure 14.25: CIRCULOGENE Theranostics, LLC: Portfolio .........................................................223
Figure 14.26: CIRCULOGENE Theranostics, LLC: SWOT Analysis .............................................224
Figure 14.27: F. Hoffmann-La Roche Ltd.: Portfolio.......................................................................226
Figure 14.28: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2020 ....................................227
Figure 14.29: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2018-2020 .................................228
Figure 14.30: F. Hoffmann-La Roche Ltd.: Sales (by Diagnostics), 2018-2020 .............................228
Figure 14.31: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020...............................229
Figure 14.32: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020.....................................230
Figure 14.33: F. Hoffmann-La Roche Ltd.: SWOT Analysis...........................................................231
Figure 14.34: Guardant Health, Inc.: Portfolio................................................................................233
Figure 14.35: Guardant Health, Inc.: Overall Financials, 2017-2019..............................................234
Figure 14.36: Guardant Health, Inc.: Revenue (by Segment), 2017-2019.....................................235
Figure 14.37: Guardant Health, Inc.: Revenue (by Region), 2017-2019........................................236
Figure 14.38: Guardant Health, Inc.: SWOT Analysis....................................................................237
Figure 14.39: Illumina, Inc.: Product Portfolio.................................................................................239
Figure 14.40: Illumina, Inc.: Overall Financials, 2017-2019............................................................240
Figure 14.41: Illumina, Inc.: Revenue (by Segment), 2017-2019...................................................241
Figure 14.42: Illumina, Inc.: Revenue (by Region), 2017-2019......................................................242
Figure 14.43: Illumina, Inc.: R&D Expenditure, 2017-2019 ............................................................243
Figure 14.44: Illumina, Inc.: SWOT Analysis..................................................................................244
Figure 14.45: Invivoscibe, Inc.: Product Portfolio ...........................................................................246
Figure 14.46: Invivoscibe, Inc.: SWOT Analysis ............................................................................247
Figure 14.47: Laboratory Corporation of America Holdings: Product Portfolio...............................249
Figure 14.48: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019.........250
Figure 14.49: Laboratory Corporation of America Holdings: Revenue
(by Segment), 2017-2019.............................................................................................251
Figure 14.50: Laboratory Corporation of America Holdings: Revenue (by Region), 2019.............252

Figure 14.51: Laboratory Corporation of America Holdings: SWOT Analysis ................................253
Figure 14.52: Mission Bio: Product Portfolio ..................................................................................255
Figure 14.53: Mission Bio: SWOT Analysis ...................................................................................255
Figure 14.54: NeoGenomics Laboratories, Inc.: Portfolio...............................................................257
Figure 14.55: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019 ............................258
Figure 14.56: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019....................258
Figure 14.57: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019.............................259
Figure 14.58: NeoGenomics Laboratories, Inc.: SWOT Analysis...................................................260
Figure 14.59: OmniSeq: Portfolio...................................................................................................262
Figure 14.60: OmniSeq: SWOT Analysis.......................................................................................262
Figure 14.61: Oxford Nanopore Technologies Ltd.: Product Portfolio............................................264
Figure 14.62: Oxford Nanopore Technologies Ltd..: SWOT Analysis ............................................264
Figure 14.63: Pacific Biosciences of California, Inc.: Product Portfolio ..........................................266
Figure 14.64: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019 .....................266
Figure 14.65: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019............267
Figure 14.66: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019................268
Figure 14.67: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019......................269
Figure 14.68: Pacific Biosciences of California, Inc.: SWOT Analysis............................................270
Figure 14.69: QIAGEN N.V.: Product Portfolio...............................................................................272
Figure 14.70: QIAGEN N.V.: Overall Financials, 2017-2019 .........................................................273
Figure 14.71: QIAGEN N.V.: Revenue (by Segment), 2017-2019.................................................274
Figure 14.72: QIAGEN N.V.: Revenue (by Region), 2017-2019....................................................275
Figure 14.73: QIAGEN N.V.: R&D Expenditure, 2017-2019 ..........................................................276
Figure 14.74: QIAGEN N.V.: SWOT Analysis................................................................................277
Figure 14.75: Quest Diagnostics Incorporated: Portfolio................................................................279
Figure 14.76: Quest Diagnostics Incorporated: Overall Financials, 2017-2019..............................280
Figure 14.77: Quest Diagnostics Incorporated: Revenue (by Segment), 2017-2019.....................281
Figure 14.78: Quest Diagnostics Incorporated: SWOT Analysis....................................................282
Figure 14.79: Thermo Fisher Scientific, Inc.: Product Portfolio ......................................................284

Figure 14.80: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019 .................................285
Figure 14.81: Thermo Fisher Scientific Inc.: Sales (by Segment): 2017-2020 ...............................286
Figure 14.82: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019.............................286
Figure 14.83: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019...................................287
Figure 14.84: Thermo Fisher Scientific Inc.: SWOT Analysis.........................................................288

Disclaimer
BIS Research provides valuable market intelligence to an exclusive group of customers in response
to orders. The report is licensed for the customer's internal use only and is subject to restrictions set
henceforth. This document and its contents are confidential and may not be further distributed,
published or reproduced, in whole or in part, by any medium or in any form for any purpose, without
the express written consent of BIS Research. Customer will not disclose the contents of the report,
whether directly in any media or indirectly through incorporation in a database, marketing list, report
or otherwise, or use or permit the use of Information to generate any statistical or other information
that is or will be provided to third parties; or voluntarily produce Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information
is available. Any recommendation contained in this report may not be suitable for all investors or
businesses. The market conclusions drawn are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by BIS Research as of the date of such statements,
are inherently subject to market fluctuations and business, economic and competitive uncertainties
and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: info@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544

Global Somatic Genetic Testing Market

Recommended

Recommended

More Related Content

What's hot

What's hot (10)

Similar to Global Somatic Genetic Testing Market

Similar to Global Somatic Genetic Testing Market (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Global Somatic Genetic Testing Market